SRPT
Sarepta Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +3.2% · net new positions -5.9% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 109 | +2 | 83.38M | $1.50B | +13 | −12 |
| Q1 2026 | 111 | +1 | 76.41M | $1.66B | +6 | −6 |
| Q4 2025 | 110 | +2 | 75.97M | $1.63B | +3 | n/a |
| Q3 2025 | 17 | 0 | 44.07M | $848.49M | +2 | −3 |
| Q2 2025 | 15 | -1 | 40.14M | $686.46M | +1 | −2 |
| Q1 2025 | 13 | -1 | 11.03M | $703.96M | +1 | −2 |
| Q4 2024 | 14 | -1 | 10.27M | $1.25B | +2 | −3 |
| Q3 2024 | 14 | +1 | 7.65M | $955.24M | +1 | n/a |
| Q2 2024 | 13 | n/a | 7.85M | $1.24B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 13.20M | +8.9% | $254.36M | 0.0% | ▲ Add | 2 | SEC ↗ ×17 |
| 2 | The Vanguard Group ✦ (passive) | 10.82M | +18.1% | $208.45M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passive) | 5.30M | +13.0% | $102.23M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Renaissance Technologies ✦ | 2.65M | +324.4% | $51.07M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 5 | Two Sigma Investments ✦ | 2.14M | -1.1% | $41.19M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 6 | D. E. Shaw & Co. ✦ | 2.01M | -55.2% | $38.68M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 7 | Morgan Stanley ✦ | 1.95M | n/a | $37.54M | 0.0% | n/c | 1 | SEC ↗ ×9 |
| 8 | Geode Capital Management ✦ (passive) | 1.72M | -8.3% | $33.17M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 9 | AQR Capital Management ✦ | 1.41M | +1015.8% | $26.40M | 0.0% | ▲ Add | 4 | SEC ↗ ×4 |
| 10 | JPMorgan Chase ✦ | 1.34M | n/a | $25.80M | 0.0% | n/c | 1 | SEC ↗ ×12 |
| 11 | Citadel Advisors ✦ | 512.48K | +69.6% | $9.88M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 12 | Bridgewater Associates ✦ | 352.27K | New | $6.79M | 0.0% | New | 1 | SEC ↗ |
| 13 | Millennium Management ✦ | 284.21K | -73.2% | $5.48M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 14 | Goldman Sachs Group ✦ | 177.15K | n/a | $3.41M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 15 | Marshall Wace ✦ | 105.11K | New | $2.03M | 0.0% | New | 1 | SEC ↗ ×3 |
| 16 | T. Rowe Price ✦ | 90.03K | +17.2% | $1.74M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 17 | Fidelity (FMR) ✦ | 14.37K | +75.4% | $276,993 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Bridgewater Associates | $6.79M | 0.0% |
| Marshall Wace | $2.03M | 0.0% |
Exited
| Wellington Management | $43.27M | was 0.0% |
| Norges Bank | $15.62M | was 0.0% |
| Fisher Asset Management | $220,761 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 339 holders, 102.41M shares, $2.16B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.